Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Henagliflozin on Myocardial Fibrosis in Obese Patients (LY2026-317-C)

14 november 2026 bijgewerkt door: Jing Ma

Effect of Henagliflozin on Myocardial Fibrosis in Obese Patients: A Prospective, Randomized, Controlled Study.

This study evaluates the anti-fibrotic efficacy and safety of henagliflozin versus metformin in non-diabetic obese patients with subclinical myocardial fibrosis, explores whether the benefit is mediated by metabolic improvement or direct myocardial protection, and aims to provide high-level evidence for early pharmacological intervention.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

This study will be based on an established specialized cohort of non-diabetic patients with simple obesity and a multi-omics database. By integrating clinical data with multidimensional information including genomics, metabolomics, and proteomics, patients at high risk of myocardial fibrosis will be identified. After myocardial fibrotic changes are further confirmed by CMR, eligible participants will be randomly assigned to the control group (metformin) or the intervention group (henagliflozin). The treatment period will be 24 weeks, followed by a 24-week safety follow-up period. The difference in the change in the degree of myocardial fibrosis before and after treatment between the two groups will be compared to determine the efficacy of henagliflozin in counteracting myocardial fibrosis in the non-diabetic obese population. This project aims to provide high-level evidence-based medical evidence for targeted pharmacological intervention of obesity-related early cardiac damage, with the goal of improving the long-term prognosis of this population.

Studietype

Ingrijpend

Inschrijving (Geschat)

100

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 65 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. BMI ≥ 28 kg/m², or waist circumference ≥ 90 cm in men or ≥ 85 cm in women, or body fat percentage ≥ 25% in men or ≥ 30% in women;
  2. Adults aged 18 to 65 years;
  3. ECV greater than 30%;
  4. No participation in other clinical trials within the past three months.

Exclusion Criteria:

  1. Diagnosed with diabetes mellitus or prediabetes;
  2. History of coronary artery disease (coronary stenosis > 50% on coronary angiography or coronary computed tomography), history of myocardial infarction, history of coronary artery bypass grafting or percutaneous coronary intervention; non-ischemic cardiovascular diseases such as idiopathic cardiomyopathy, valvular disease, congenital heart disease, or cor pulmonale; arrhythmia or bundle branch block on electrocardiogram; implantation of a cardiac pacemaker or defibrillator;
  3. Uncontrolled hypertension: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg during the screening visit (mean of three blood pressure measurements in the supine position);
  4. Symptomatic hypotension and/or systolic blood pressure < 90 mmHg at V1 or V2, or patients judged by the clinician to have hypovolemia;
  5. Use within 3 months of: 1) medications that may affect body weight or glucose metabolism, including systemic glucocorticoids (excluding topical, ophthalmic, nasal spray, or inhaled preparations; excluding low-dose or overnight dexamethasone suppression test use), growth hormone, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic/tetracyclic antipsychotic drugs, other psychiatric medications or sedatives (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts), etc.; 2) traditional Chinese medicines, Chinese patent medicines, herbal medicines, health supplements, meal replacements, etc., with weight-loss or glucose-lowering effects; 3) use of or current use of the following weight-loss drugs or drugs containing the following ingredients, such as: sibutramine hydrochloride, orlistat, phentermine, phenylpropanolamine, clobenzorex, fenfluramine, amfepramone, lorcaserin, phentermine/topiramate combination, naltrexone/bupropion combination, etc.; 4) use of glucose-lowering drugs, such as metformin, α-glucosidase inhibitors, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, thiazolidinediones (TZDs), insulin, etc.;
  6. Other endocrine and metabolic diseases such as hyperthyroidism, hypothyroidism, acromegaly, diabetes insipidus, or Cushing's syndrome;
  7. Concurrent malignant tumors;
  8. Severe liver disease (Child-Pugh class C) or liver enzymes (ALT/AST) > 3 times the upper limit of normal;
  9. Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m²;
  10. Cognitive impairment, or concomitant infectious or autoimmune diseases;
  11. History of recurrent urinary or reproductive tract infections;
  12. Patients who refuse henagliflozin or metformin treatment, or who are allergic to henagliflozin, metformin, or their excipients; those with incomplete questionnaires or incomplete data;
  13. Pregnant or breastfeeding women.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Interventie Groep

Oral henagliflozin 10 mg once daily for 24 weeks, administered at a fixed dose without adjustment. Used in non-diabetic obese patients with subclinical myocardial fibrosis as an off-label investigational treatment.

Actieve vergelijker: Control Group

oral metformin tablets 2000 mg/day; or the maximum tolerated dose (≥1000 mg/day).

Oral metformin titrated to 2000 mg/day (1000 mg twice daily), or the maximum tolerated dose (≥1000 mg/day), for 24 weeks. Dose titration: 500 mg twice daily for weeks 1-2, then 1000 mg twice daily from week 3 if tolerated.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from Baseline in Myocardial Extracellular Volume (ECV) Fraction at 24 Weeks
Tijdsspanne: Baseline to Week 24

Change from baseline in myocardial extracellular volume (ECV) fraction, as measured by cardiac magnetic resonance (CMR) T1 mapping pre- and post-contrast. ECV is calculated from pre- and post-contrast T1 relaxation times and the patient's hematocrit. The between-group difference in ΔECV (Henagliflozin vs. Metformin) will be compared; continuous data will be summarized as mean ± SD and analyzed using mixed-effects models.

Baseline to Week 24

Secundaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
Change from Baseline in Epicardial Adipose Tissue (EAT) Volume at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Left Ventricular Ejection Fraction (LVEF) at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Cardiac Output at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Heart Rate at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Peak Filling Rate at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Stroke Volume Index (BSA-corrected) at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in End-Systolic Volume Index (BSA-corrected) at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in End-Diastolic Volume Index (BSA-corrected) at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Left Ventricular Mass Index (BSA-corrected) at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Early-to-Late Filling Ratio (E/A) at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in LV Mass to End-Diastolic Volume Ratio (MVR) at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Cardiac Index at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Body Weight at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Body Mass Index (BMI) at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Systolic Blood Pressure at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Diastolic Blood Pressure at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Glycated Hemoglobin (HbA1c) at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Fasting Plasma Glucose at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in HOMA-IR (Insulin Resistance Index) at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Total Cholesterol at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Triglycerides at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24
Change from Baseline in High-sensitivity CRP (hsCRP) at 24 Weeks
Tijdsspanne: Baseline to Week 24
Baseline to Week 24

Andere uitkomstmaten

Uitkomstmaat
Tijdsspanne
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Tijdsspanne: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Genitourinary Tract Infections
Tijdsspanne: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Gastrointestinal Adverse Events
Tijdsspanne: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Ketoacidosis
Tijdsspanne: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Serious Adverse Events (SAEs)
Tijdsspanne: Up to 48 Weeks
Up to 48 Weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Hoofdonderzoeker: Jing Ma, Department of Endocrinology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

1 oktober 2028

Studie voltooiing (Geschat)

1 oktober 2028

Studieregistratiedata

Eerst ingediend

1 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

14 november 2026

Eerst geplaatst (Werkelijk)

19 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

19 november 2026

Laatste update ingediend die voldeed aan QC-criteria

14 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • LY2026-317-C

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .